Ginkgo reports Q1 2026 results, completes biosecurity divestiture
Revenue fell to $19M from $38M, net loss narrowed to $76M, and Nebula lab expansion targets doubling size.
See the latest news and media coverage for Ginkgo. We track all announcements, press releases, and industry mentions in real time, all in one place.
Autonomous lab platform for biotechnology R&D
ginkgo.bioLast updated
In short: Ginkgo implemented major cost-cutting measures, including workforce reductions and biosecurity divestitures, to focus on its autonomous lab platform.
Revenue fell to $19M from $38M, net loss narrowed to $76M, and Nebula lab expansion targets doubling size.
The presentation and Q&A session will be on May 7, 2026 after market close.
Revenue decreased 24% in Q4 to $33M, and the company will sell its biosecurity business to focus on autonomous labs, with a $47M contract won.
The presentation and Q&A will be held on February 26, 2026 after market close.
High Yield- Join thousands of investors using free stock market insights and expert analysis to identify stronger growth opportunities before major price moves. Ginkgo Bioworks...
As of Friday, May 08, Ginkgo Bioworks Holdings, Inc.'s DNA share price has dipped by 13.95%, which has investors questioning if this is right time...
BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to...
Ginkgo Bioworks has been awarded a contract through the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium).
Track Ginkgo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.